Lansforsakringar Fondforvaltning Ab (Publ) Halozyme Therapeutics, Inc. Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $15.9 Billion
- Q1 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 9,457 shares of HALO stock, worth $594,845. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,457
Previous 8,907
6.17%
Holding current value
$594,845
Previous $425,000
41.88%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
582Shares Held
122MCall Options Held
308KPut Options Held
186K-
Black Rock Inc. New York, NY17.6MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$807 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$381 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$245 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$231 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.76B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...